FREE PREMIUM SUBSCRIPTION FOR 14 DAYS!

ChemoCentryx Stock News NASDAQ:CCXI

ChemoCentryx: CRL Less Likely

03:04pm, Sunday, 25'th Jul 2021 Seeking Alpha
Read more
This report studies the Anca Vasculitis Drug Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Anca Vasculitis Drug market segmented by company, [] Read more
Los Angeles, July 14, 2021 (GLOBE NEWSWIRE) -- Hidradenitis Suppurativa Pipeline Landscape: Novel Emerging Therapies and Key Pharmaceutical Companies Reinvigorates the Pipeline Landscape The Hidradenitis Suppurativa pipeline landscape includes several therapies with different mechanisms of action currently being studied with great market potential. Ongoing scientific research has provided greater sophistication and a clearer understanding of the mechanisms of therapeutic interventions for Hidradenitis suppurativa. DelveInsight''s '' Hidradenitis Suppurativa Pipeline Insights '' report presents an exhaustive coverage of the available therapies, Hidradenitis Suppurativa emerging drug therapies in different phases of clinical development, key companies working to advance the Hidradenitis Suppurativa pipeline therapies, and the future market scope of the space. Some of the notable pointers extracted from the Hidradenitis Suppurativa (HS) Pipeline report: DelveInsight''s analysis depicts a robust Hidradenitis Suppurativa Pipeline with 25+ active players in the domain working on 25+ pipeline therapies. Read more

Is Now the Time to Buy ChemoCentryx Stock?

10:44am, Saturday, 10'th Jul 2021 The Motley Fool
Analysts following this risky biotech stock have changed their tune. Read more

A Risky Yet Potentially Lucrative Bet

07:31am, Saturday, 10'th Jul 2021 Bitcoin Ethereum News
The post A Risky Yet Potentially Lucrative Bet appeared on BitcoinEthereumNews.com . With shares sitting 73% into the red in 2021, its safe to say, Chemocentryx (CCXI) investors have endured a difficult year so far. The alarming decline has mostly been due Read more

ChemoCentryx Inc Shares Close the Day 11.1% Higher - Daily Wrap

01:16am, Saturday, 10'th Jul 2021 Kwhen Finance
ChemoCentryx Inc (CCXI) shares closed today 11.1% higher than it did at the end of yesterday. The stock is currently flat year-to-date, down 75.5% over the past 12 months, and up 214.6% over the past five years. Today, the Dow Jones Industrial Average rose 1.3%, and the S&P 500 rose 1.1%. Trading Activity Shares traded as high as $17.13 and as low as $12.71 this week.Shares closed 76.1% below its 52-week high and 76.0% above its 52-week low.Trading volume this week was 26.8% lower than the 10-day average and 21.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date is the same as the peer average. The company's stock price performance over the past 12 months lags the peer average by -780.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected] © 2020 Kwhen Inc. Read more

Chemocentryx: A Risky Yet Potentially Lucrative Bet

08:31pm, Friday, 09'th Jul 2021 TipRanks
With shares sitting 73% into the red in 2021, its safe to say, Chemocentryx (CCXI) investors have endured a difficult year so far. The alarming decline has mostly bee Read more
SAN DIEGO, July 7, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of ChemoCentryx Inc. ("ChemoCentryx" or the "Company") ( NASDAQ: CCXI) against certain of its current and Read more

: ChemoCentryx upgraded to buy from hold at Stifel Nicolaus

10:45am, Wednesday, 07'th Jul 2021 MarketWatch
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news. Read more

Why This ChemoCentryx Analyst Is Bullish

07:20pm, Tuesday, 06'th Jul 2021 Business Insider Markets
H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ: CCXI ) following an amended new drug application for avacopan. Read more

ChemoCentryx Stock Is Approaching A Key Level

05:55pm, Tuesday, 06'th Jul 2021 Benzinga
ChemoCentryx Inc. (NASDAQ: CCXI ) shares traded higher Tuesday after the company announced it filed an amendment to its New Drug Application for avacopan for the treatment of anti-neutrophil cytoplasmic yutoantibody associated vasculitis. The U.S. Food and Drug Administration (FDA) filing was set to have a goal date of Oct. 7, 2021. ChemoCentryx was up 9.71% at $14.46 at last check. ChemoCentryx Daily Chart Analysis Shares saw a very large dip in early May 2021 and now look to be making a comeback after forming higher Full story available on Benzinga.com Read more

ChemoCentryx Rises on Update to FDA Vasculitis-Drug Filing

03:01pm, Tuesday, 06'th Jul 2021 The Street
ChemoCentryx jumps after filing with the FDA, and amending, a new-drug application for a vasculitis treatment. Read more
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ChemoCentryx, Inc. ("ChemoCentryx" or "the Company") (NASDAQ: CCXI ) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ChemoCentryx securities between November 26, 2019 and May 6, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm''s site: www.bgandg.com/ccxi . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. On May 4, 2021, the U.S. Food and Drug Administration ("FDA") released a "Briefing Document" concerning ChemoCentryx''s drug candidate avacopan, which is Full story available on Benzinga.com Read more
Following consultations with the FDA, ChemoCentryx Inc (NASDAQ: CCXI ) filed an amendment to its marketing application seeking approval for avacopan to treat Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis addressing concerns raised during the FDA Advisory Committee meeting in May. The FDA has indicated that the filing constitutes a significant Full story available on Benzinga.com Read more

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE